You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. 11a Sustainable Recovery of Fuel Cell and Electrolyzer Materials

    SBC: TETRAMER TECHNOLOGIES LLC            Topic: C5611a

    Renewable energy sources are experiencing a surge of growth due to rising power demand but suffer asynchronous production relative to societal needs. To balance the overproduction during low demand and underproduction during high demand, proton exchange membrane (PEM) based electrolyzers (capable of producing zero-carbon, green hydrogen) and fuel cells (for clean electricity generation and zero em ...

    SBIR Phase I 2023 Department of Energy
  2. 20c Polymer Composites with Enhanced Thermal Conductivity

    SBC: TETRAMER TECHNOLOGIES LLC            Topic: C5620c

    Plastics (polymers) are used widely in energy, industry, and defense sectors due to their low cost and weight, processibility, and electrical insulation properties. Unfortunately, this class of materials is also thermally insulating, which restricts their usefulness in applications where heat is generated and has a direct effect on the performance (e.g. electronics and computing, LED lighting, hea ...

    SBIR Phase I 2023 Department of Energy
  3. 41f Development of a Continuous Cost Effective Kr Xe Capture Process for Nuclear Fuels Reprocessing

    SBC: TETRAMER TECHNOLOGIES LLC            Topic: C5641f

    Nuclear energy is one of the most favorable and cheapest alternatives to fossil fuels, and it can be scaled up to meet global energy demands. The mass deployment of nuclear energy as a low-emissions source requires the reprocessing of used nuclear fuel to recover fissile materials and mitigate radioactive waste. A major concern with reprocessing used nuclear fuel is the release of gaseous radionuc ...

    SBIR Phase I 2023 Department of Energy
  4. Development Of A Smart Vision And AI-Driven Peach Thinning Software (A-EYE)

    SBC: ADVENT INNOVATIONS LTD CO            Topic: 813

    Peach thinning is a major expense for peach farming operations accounting for 60% of the totalcost during annual maintenance. The commonly used bloom thinning methods include handchemical and mechanical thinning. Hand thinning and mechanical thinning are the most widelyused but these methods are labor intensive inaccurate and have no built-in intelligence to properlyguide the thinning process.Adve ...

    SBIR Phase I 2023 Department of Agriculture
  5. Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis

    SBC: GLYCOPATH INC            Topic: 400

    Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing natural compound emodin as a therapy for alcoholic cardiomyopathy

    SBC: AcePre, LLC            Topic: NIAAA

    Project Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development

    SBC: FIBROTHERAPEUTICS INC            Topic: NHLBI

    Abstract Our long-term objective is to fill the unmet need for treatments for heart failure (HF). Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). We have shown the beneficial effects of CSD in two independent ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis

    SBC: FibroBiologics, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Developing novel LOX inhibitors to target chemotherapy resistant TNBC

    SBC: LOXIGEN, INC.            Topic: 102

    PROJECT SUMMARY Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It accounts for ~15% of all breast cancer yet is responsible for 30% of breast cancer deaths. TNBC is treated primarily by conventional chemotherapy; however, resistance to therapy is common, leading to high mortality rates. Importantly, the benefit of current therapeutic strategies used in chemoresi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.

    SBC: Zylo Therapeutics Inc.            Topic: NIAMS

    Project Summary/Abstract Approximately 500,000 people in the U.S. suffer from cutaneous lupus lesions (CLE), with a significant impact on quality of life.4 Yet, there is no cure, the treatment options are limited, and no new drug has been FDA- approved for over 50 years.84 As such, CLE represents a high unmet need for directed therapeutics. Skin lesions are caused by a complex autoimmune response ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government